PACAP-targeted antibody Lu AG09222 inhibits vasodilation in healthy volunteers

Lundbeck Moves PACAP-Targeting Antibody into Multinational Phase 2b Clinical Trial.

M Meglio - Patient Care (Online), 2024 - search.ebscohost.com
Lundbeck has initiated a phase 2 clinical trial called PROCEED to evaluate the effectiveness
and safety of Lu AG09222, a potential treatment for migraines. The trial will involve 498 …
相关文章